Momelotinib Dihydrochloride

N/A

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameMomelotinib Dihydrochloride
Drug Alias Name莫洛替尼momelotinib莫美替尼momelotinibum莫莫替尼 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsActivin receptor type-1 inhibitorsTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK2Activin receptor type-1Tyrosine-protein kinase JAK1
Therapy Area/IndicationsVEXAS SyndomeSplenomegalyPrimary Myelofibrosis +[12] 
Global Approved IndicationsSplenomegalyPrimary MyelofibrosisMyeloproliferative Disorders +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/09/15
Country/TerritoryCzechiaBelgiumBulgaria +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGilead Sciences IncCytopia Pty Ltd
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of LincolnSierra Oncology LLCGlaxosmithkline Trading Services Ltd +[7] 
Inactive CompaniesSierra Oncology Inc
Active IndicationsVEXAS SyndomeSplenomegalyPrimary Myelofibrosis +[8] 
Inactive IndicationsCarcinoma, Non-Small-Cell LungPancreatic Intraductal NeoplasmsCarcinoma, Pancreatic Ductal +[4] 

Other Information

ATC CodeL01EJ04
Related LinksWikipediaDrugBankKEGG